University of Manchester-ko ikertzaileekin lankidetzan egindako argitalpenak (40)

2022

  1. Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study

    PLoS Medicine, Vol. 19, Núm. 2

2020

  1. Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 6, pp. 605-613

2017

  1. Genetic variations in the alanine–glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis

    Amino Acids, Vol. 49, Núm. 6, pp. 1133-1141

2014

  1. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: An association driven by high inflammatory burden

    Rheumatology (United Kingdom), Vol. 53, Núm. 1, pp. 131-137

  2. Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis

    Atherosclerosis, Vol. 237, Núm. 1, pp. 38-44

2012

  1. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 14, Núm. 4

  2. Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis

    Journal of Rheumatology, Vol. 39, Núm. 2, pp. 218-225

2011

  1. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

    Journal of Human Hypertension, Vol. 25, Núm. 11, pp. 699-702

  2. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?

    Angiology, Vol. 62, Núm. 2, pp. 167-175

  3. Dyslipidaemia in rheumatological autoimmune diseases

    Open Cardiovascular Medicine Journal, Vol. 5, Núm. SPEC. ISSUE, pp. 64-75

  4. Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: Association with hypertension, but not therapy or inflammation

    Clinical Rheumatology, Vol. 30, Núm. 4, pp. 477-484

  5. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 6, pp. 1025-1032

2010

  1. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 3, pp. 517-521

  2. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients

    Musculoskeletal Care, Vol. 8, Núm. 1, pp. 2-9

  3. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk?

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 683-688

  4. Subclinical peripheral arterial disease in rheumatoid arthritis

    Atherosclerosis, Vol. 212, Núm. 1, pp. 305-309

  5. Target organ damage in patients with rheumatoid arthritis: The role of blood pressure and heart rate

    Atherosclerosis, Vol. 209, Núm. 1, pp. 255-260

  6. What predicts obesity in patients with rheumatoid arthritis An investigation of the interactions between lifestyle and inflammation

    International Journal of Obesity, Vol. 34, Núm. 2, pp. 295-301

2009

  1. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: The role of obesity and smoking

    Atherosclerosis, Vol. 204, Núm. 1, pp. 178-183

  2. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis

    European Journal of Preventive Cardiology, Vol. 16, Núm. 2, pp. 188-194